Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Children's Oncology Group0 个研究点目标入组 9,483 人开始时间: 2013年10月10日最近更新: 2021年4月12日

适应症

试验速览

暂无简介。

•Patients must be enrolled on the classification study AALL08B1 prior to treatment and enrollment on AALL0932 (except for B-LLy patients who are not eligible for AALL08B1).
•B-ALL patients must be >365 days and <10 years of age. B-LLy patients must be >365 days and =<30.99 years of age.
•B-ALL patients must have an initial white blood cell count <50000/µL.
•Patients must have newly diagnosed NCI Standard Risk B-ALL or B-LLy Murphy Stage I or II. Patients with Down syndrome are also eligible.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or B-LLy or for any cancer diagnosed previously, with the exception of steroid pretreatment and intrathecal cytarabine.
•Patients with CNS3 positive disease.
•B-ALL patients with testicular leukemia.
•B-LLy patients with
•- T-lymphoblastic lymphoma
•- Morphologically unclassifiable lymphoma
•- Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma
•- M2 (5%-25% blasts) or M3 (>25% blasts) marrow.

发起方